Journal of Digestive Cancer Research

Korean Society of Gastrointestinal Cancer Research (대한소화기암연구학회)
권호 표지

FOLFIRI Regimen as a Second-line Chemotherapy after Failure of First-line Chemotherapy in Advanced Gastric Cancer

진행성 위암에서 1차 항암화학요법에 실패한 환자에서 2차 항암화학요법으로 FOLFIRI요법의 효용성에 대한 연구

  • Yong Kang Lee (Department of Internal Medicine and Institute of Gastroenterology, Yonsei University College of Medicine) ;
  • Jae Hyun Kim (Department of Internal Medicine and Institute of Gastroenterology, Kosin University Gospel Hospital) ;
  • Jun Chul Park (Department of Internal Medicine and Institute of Gastroenterology, Yonsei University College of Medicine) ;
  • Hee Seok Moon (Department of Internal Medicine and Institute of Gastroenterology, Dong-A University Hospital) ;
  • Sung Eun Kim (Department of Internal Medicine and Institute of Gastroenterology, Kosin University Gospel Hospital) ;
  • Jin Seok Jang (Department of Internal Medicine and institute of Gastroenterology, Chungnam National University Hospital) ;
  • Joo Young Cho (Department of Internal Medicine and institute of Gastroenterology, Cha University College of Medicine, Bundang Cha Hospital) ;
  • Eun Sun Kim (Department of Internal Medicine and institute of Gastroenterology, Korea University College of Medicine, Anam Hospital) ;
  • Si Hyung Lee (Department of Internal Medicine and institute of Gastroenterology, Yeungnam University College of Medicine) ;
  • Sang Kil Lee (Department of Internal Medicine and Institute of Gastroenterology, Yonsei University College of Medicine)
  • 이용강 (연세대학교 의과대학 소화기내과) ;
  • 김재현 (고신대학교 의과대학 소화기내과) ;
  • 박준철 (연세대학교 의과대학 소화기내과) ;
  • 문희석 (동아대학교 의과대학 소화기내과) ;
  • 김성은 (고신대학교 의과대학 소화기내과) ;
  • 장진석 (충남대학교 의과대학 소화기내과) ;
  • 조주영 (차의과학대학교 소화기내과) ;
  • 김은선 (고려대학교 의과대학 소화기내과) ;
  • 이시형 (영남대학교 의과대학 소화기내과) ;
  • 이상길 (연세대학교 의과대학 소화기내과)
  • Received : 2017.10.24
  • Accepted : 2017.12.11
  • Published : 2017.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Second line chemotherapy is often considered in advanced gastric cancers. We assessed irinotecan in combination with fluorouracil in patients experienced diseases progression after first line chemotherapy. Methods: Prospective trial was done at 7 centers in republic of Korea. Patients aged 18 years or older with advanced gastric adenocarcinoma and disease progression on or within 4 months after first-line chemotherapy were assigned to receive irinotecan 180 mg/m2 and 5-fluorouraicl 400 mg/m2 intravenously bolus injection on days 1 and leucovorin 200 mg/m2 for 2 hours and 5-fluorouracil 600 mg/m2 for 22 hours intravenously infusion on day 2 of a 14-day cycle (FOLFIRI group). The primary endpoint was objective tumor response (OR). Efficacy analysis was by per-protocol, and safety analysis included all patients who received at least one treatment with study drug. Results: Between January 1, 2014 and December 31, 2016, 28 patients were assigned to FOLFIRI treatment. Of those 20 patients were completed the study protocol. Per-protocol analysis, two patients among 20 subjects (10.0%) showed partial response. Overall survivals of FOLFIRI group; median 10.1 months [95% CI 4.9-15.3] Grade 3 and higher adverse event that occurred about 5%, but grade 3 or higher febrile neutropenia or life threatening complication was not reported. Conclusion: Combination chemotherapy with irinotecan, 5-FU, and LV is feasible in gastric cancer patients previously treated with platinum-based chemotherapy

Keywords

References

  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
  2. Lochhead P, El-Omar EM. Gastric cancer. Br Med Bull 2008;85:87-100.
  3. Izuishi K, Mori H. Recent strategies for treating stage IV gastric cancer: Roles of palliative gastrectomy, chemotherapy, and radiotherapy. J Gastrointestin Liver Dis 2016;1:87-94.
  4. Bang Y, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-697.
  5. Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): A phase III trial. Lancet Oncol 2008;3:215-221.
  6. Ajani JA, Barthel JS, Bekaii-Saab T, et al. Gastric cancer. J Natl Compr Canc Netw 2010;4:378-409.
  7. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: A systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006;24:2903-2909.
  8. Ford HER, Marshall A, Bridgewater JA, et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): An open-label, phase 3 rando mised controlled trial. Lancet Oncol 2014;1:78-86.
  9. Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): An international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014;383:31-39.
  10. Yilmaz U, Oztop I, Alacacioglu A, Yaren A, Tarhan O, Somali I. Irinotecan combined with infusional 5-fluorouracil and high-dose leucovorin for the treatment of advanced gastric carcinoma as the first-line chemotherapy. Chemotherapy 2006;52:264-270.
  11. Baek JH, Kim JG, Sohn SK, et al. Biweekly irinotecan and cisplatin as second-line chemotherapy in pretreated patients with advanced gastric cancer: A multicenter phase II study. J Korean Med Sci 2005;6:966-970.
  12. Kim S, Oh SY, Kwon H, et al. A phase II study of irinotecan with bi-weekly, low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as salvage therapy for patients with advanced or metastatic gastric cancer. Jpn J Clin Oncol 2007;10:744-749.
  13. Kim SH, Lee G, Go SI, et al. A phase II study of irinotecan, continuous 5-fluorouracil, and leucovorin (FOLFIRI) combination chemotherapy for patients with recurrent or metastatic gastric cancer previously treated with a fluoropyrimidine-based regimen. Am J Clin Oncol 2010;6:572-576.
  14. Rosati G, Cordio S, Caputo G, et al. Phase II trial of a biweekly regimen of fluorouracil and leucovorin plus irinotecan in patients with previously untreated advanced gastric cancer. J Chemother 2007;5:570-576.
  15. Yilmaz U, Oztop I, Alacacioglu A, Yaren A, Tarhan O, Somali I. Irinotecan combined with infusional 5-fluorouracil and high-dose leucovorin for the treatment of advanced gastric carcinoma as the first-line chemotherapy. Chemotherapy 2006;5:264-270.
  16. Bouche O, Raoul JL, Bonnetain F, et al. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: A federation francophone de cancerologie digestive group study--FFCD 9803. J Clin Oncol 2004;21:4319-4328.
  17. Thuss-Patience PC, Kretzschmar A, Bichev D, et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer - a randomised phase III study of the arbeitsgemeinschaft internistische onkologie (AIO). Eur J Cancer 2011;15:2306-2314.
  18. Wesolowski R, Lee C, Kim R. Is there a role for second-line chemotherapy in advanced gastric cancer? Lancet Oncol. 2009;9:903-912.
  19. Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): A double-blind, randomised phase 3 trial. Lancet Oncol 2014;11:1224-1235.